ÂÜÀòÂÒÂ×

Todd Bosanac has over 17 years of experience in the pharmaceutical industry. Todd began their career in 2005 at Boehringer Ingelheim as a Senior Scientist, where they were responsible for driving the identification of hit compounds and the optimization of lead molecules. Todd then progressed to Principal Scientist, where they were a contributor in a cross-disciplinary team delivering novel and innovative new target concepts in the cardiovascular therapeutic area. In 2017, they moved to Alkermes as a Research Fellow. In 2018, they joined Disarm Therapeutics as VP Chemistry and Senior Director Molecular Discovery. Most recently, they have been appointed Vice President, Medicinal Chemistry at Rectify Pharma, a position they have held since 2022.

Todd Bosanac attained a Postdoc from the University of Pennsylvania in Chemistry from 2003 to 2005. Prior to that, they earned a PhD in Chemistry from the University of Pittsburgh from 1998 to 2003.